Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment

NCT04874948 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Tuberculosis
Tuberculosis, Pulmonary
Bacterial Infections Respiratory
Lung Diseases
Mycobacterium Infections

Interventions

DRUG: 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043

Sponsor

Michael Hoelscher

Collaborators

[object Object]